A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 33, Issue 5, 2006, Pages 543-570

  Zandvliet, Anthe S ^a   Schellens, Jan H M ^b,c   Copalu, William ^d   Beijnen, Jos H ^a,c   Huitema, Alwin D R ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d EISAI CO LTD   (Japan)

Author keywords

Distribution; Erythrocytes; Indisulam; Mechanistic model; NONMEM; Physiologically based; Plasma protein binding; Population pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE; INDISULAM; SERUM ALBUMIN;

AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG ERYTHROCYTE LEVEL; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; FEMALE; HEMATOCRIT; HUMAN; INTERSTITIAL FLUID; JAPAN; MAJOR CLINICAL STUDY; MALE; NONLINEAR SYSTEM; PHARMACOGENETICS; POPULATION MODEL; PREDICTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SIMULATION;

ALGORITHMS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PROTEINS; CARBONIC ANHYDRASES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE I AS TOPIC; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTES; EUROPEAN CONTINENTAL ANCESTRY GROUP; EXTRACELLULAR FLUID; HUMANS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; MULTIVARIATE ANALYSIS; PROTEIN BINDING; REGRESSION ANALYSIS; SULFONAMIDES; TISSUE DISTRIBUTION;

EID: 33748660661     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-006-9021-5     Document Type: Article

References (31)

1. Y. Ozawa, N. H. Sugi, T. Nagasu, T. Owa, T. Watanabe, N. Koyanagi, H. Yoshino, K. Kitoh, and K. Yoshimatsu. E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. Eur. J. Cancer 37(17):2275-2282 (2001).
2. T. Owa, H. Yoshino, T. Okauchi, K. Yoshimatsu, Y. Ozawa, N. H. Sugi, T. Nagasu, N. Koyanagi, and K. Kitoh. Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J. Med. Chem. 42(19):3789-3799 (1999).
3. K. Fukuoka, J. Usuda, Y. Iwamoto, H. Fukumoto, T. Nakamura, T. Yoneda, N. Narita, N. Saijo, and K. Nishio. Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells. Invest. New Drugs 19(3):219-227 (2001).
4. E. Raymond, W. W. Bokkel Huinink, J. Taieb, J. H. Beijnen, S. Faivre, J. Wanders, M. Ravic, P. Fumoleau, J. P. Armand, and J. H. M. Schellens. Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer. J. Clin. Oncol. 20(16):3508-3521 (2002).
5. C. J. A. Punt, P. Fumoleau, B. van de Walle, M. N. Faber, M. Ravic, and M. Campone. Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG). Ann. Oncol. 12(9):1289-1293 (2001).
6. C. Dittrich, H. Dumez, H. Calvert, A. Hanauske, M. Faber, J. Wanders, S. M. Yule, M. Ravic, and P. Fumoleau. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors. Clin. Cancer Res. 9(14):5195-5204 (2003).
7. C. Terret, S. Zanetta, H. Roche, J. H. M. Schellens, M. N. Faber, J. Wanders, M. Ravic, and J. P. Droz. Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG). Eur. J. Cancer 39(8):1097-1104 (2003).
8. E. Raymond, P. Fumoleau, H. Roche, J. H. M. Schellens, C. Dittrich, C. J. A. Punt, J. P. Droz, A. H. Calvert, A. van Oosterom, J. Wanders, and M. Ravic. Combined results of 4 phase I and pharmacokinetic studies of E7070, a novel chloroindoly-sulphonamide inhibiting the activation of cdk2 and cyclin E. Clin. Cancer Res. 6:4529s (2000).
9. P. Fumoleau, P. Viens, P. H. Cottu, J. De Grève, M. Marty, S. Delaloge, D. Miles, S. O'Reilly, A. Wardley, P. Schmid, M. Ravic, and M. Paternoster. A multi center phase II study of E7070, a chloroindolyl-sulfonamide anticancer agent in anthracycline and taxane pre treated breast cancer. 26th San Antonio Breast Cancer Symposium, 2003 No. 535, Abstract.
10. P. N. Mainwaring, E. Van Cutsem, J. L. Van Laethem, D. Propper, C. Twelves, J. Bridgewater, B. Audhuy, J. Carmichael, C. J. A. Punt, J. Cassidy, N. Stuart, and M. Ravic. A multicentre randomised phase II study of E7070 in patients with colorectal cancer who have failed 5-fluorouracil-based chemotherapy. Proc. Am. Soc. Clin. Oncol. (ASCO Annual Meeting) 21:153a (2002) No. 611, Abstract.
11. H. Raftopoulos, B. Escudier, G. Renshaw, P. N. Lara, J. Dutcher, D. Nanus, D. P. Petrylak, and L. Sacris. A phase II multicenter study of the cyclin-dependent kinase inhibitor indisulam in patients with inoperable and/or metastatic renal cell carcinoma (RCC). J. Clin. Oncol - ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22(14S) (2004) No. 4629, Abstract.
12. C. van Kesteren, R. A. A. Mathôt, E. Raymond, J. P. Armand, C. Dittrich, H. Dumez, H. Roche, J. P. Droz, C. J. A. Punt, M. Ravic, J. Wanders, J. H. Beijnen, P. Fumoleau, and J. H. M. Schellens. Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation. J. Clin. Oncol. 20(19):4065-4073 (2002).
13. Y. Yamada, N. Yamamoto, T. Shimoyama, A. Horiike, Y. Fujisaka, K. Takayama, T. Sakamoto, Y. Nishioka, S. Yasuda, and T. Tamura. Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days. Cancer Sci. 96(10):721-728 (2005).
14. A. S. Zandvliet, W. Copalu, J. H. Schellens, J. H. Beijnen, and A. D. Huitema. Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes. Drug Metab. Dispos. 34(6):1041-1046 (2006).
15. R. J. Baker, D. D. Kozoll, and K. A. Meyer. The use of surface area as a basis for establishing normal blood volume. Surg. Gynecol. Obstet. 104(2):183-189 (1957).
16. R. Kawai, D. Mathew, C. Tanaka, and M. Rowland. Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human. J. Pharmacol. Exp. Ther. 287(2):457-468 (1998).
17. W. F. Bayne, F. T. Tao, G. Rogers, L. C. Chu, and F. Theeuwes. Time course and disposition of methazolamide in human plasma and red blood cells. J. Pharm. Sci. 70(1):75-81 (1981).
18. G. E. Morgan, M. S. Mikhail, M. J. Murray, and C. P. Larson. Clinical Anesthesiology, 3rd edn. McGraw-Hill, Medical Publishing Division, New York, 2002.
19. K. Aukland, and R. K. Reed. Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. Physiol. Rev. 73(1):1-78 (1993).
20. S. L. Beal, A. J. Boeckman, and L. B. Sheiner. NONMEM User's Guides. University of California at San Francisco, San Francisco, CA, 1988.
21. B. Efron, and G. Gong. A leisurely look at the bootstrap, the jackknife and cross-validation. Am. Stat. 37:36-48 (1983).
22. H. J. G. D. van den Bongard, D. Pluim, R. C. Waardenburg, M. Ravic, J. H. Beijnen, and J. H. M. Schellens. In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood. Anticancer Drugs 14(6):405-410 (2003).
23. W. F. Bayne, L. C. Chu, and F. Theeuwes. Acetazolamide binding to two carbonic anhydrase isoenzymes in human erythrocytes. J. Pharm. Sci. 68(7):912-913 (1979).
24. T. Hasegawa, K. Hara, and S. Hata. Binding of dorzolamide and its metabolite, N-deethylated dorzolamide, to human erythrocytes in vitro. Drug Metab. Dispos. 22(3):377-382 (1994).
25. J. Singh, and P. Wyeth. The enzyme-inhibitor approach to cell-selective labelling-I. Sulphonamide inhibitors of carbonic anhydrase as carriers for red cell labelling: in vitro uptake of pIBS by human red blood cells. Int. J. Rad. Appl. Instrum. A 42(3):251-259 (1991).
26. E. Snoeck, P. Jacqmin, A. van Peer, and M. Danhof. A combined specific target site binding and pharmacokinetic model to explore the non-linear disposition of draflazine. J. Pharmacokinet. Biopharm. 27(3):257-281 (1999).
27. J. H. Beumer, M. J. X. Hillebrand, D. Pluim, H. Rosing, K. Foley, S. M. Yule, J. H. M. Schellens, and J. H. Beijnen. Human metabolism of [(14)C]indisulam following i.v. infusion in cancer patients. Invest. New Drugs 23(4):317-330 (2005).
28. M. Kimura, I. Ieiri, K. Mamiya, A. Urae, and S. Higuchi. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther. Drug Monit. 20(3):243-247 (1998).
29. J. A. Goldstein. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol. 52(4):349-355 (2001).
30. L. B. Sheiner, and J. Wakefield. Population modelling in drug development. Stat. Methods Med. Res. 8(3):183-193 (1999).
31. C. van Kesteren, A. S. Zandvliet, M. O. Karlsson, R. A. A. Mathôt, C. J. A. Punt, J. P. Armand, E. Raymond, A. D. R. Huitema, C. Dittrich, H. Dumez, H. Roche, J. P. Droz, M. Ravic, S. M. Yule, J. Wanders, J. H. Beijnen, P. Fumoleau, and J. H. M. Schellens. Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest. New Drugs 23(3):225-234 (2005).